Literature DB >> 30281780

Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes.

X Hu3, J Tang2, X Hu3, P Bao4, J Pan1, Y Ou5, W Deng6, Y Liang1.   

Abstract

In this study, we aimed to explore the effects of imatinib on the proliferation of rheumatoid arthritis synovial cell (RA-FLS) and inflammatory responses by regulating CSF1R. Differential genes were screened via microarray analysis, followed by being analysed through the weighted co-expression network (WGCNA) network, that included module and cluster analysis. The relationship between imatinib and genes was visualized using the Search Tool for the Retrieval of Interacting Genes (STITCH) database. Expressions of mRNA and protein were determined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot, respectively. Cell viability was examined via clone formation assay, while cell cycle and apoptosis were analysed through flow cytometry analysis. The hub gene CSF1R was ultimately determined by microarray analysis and WGCNA analysis. Colony-stimulating-factor receptor-1 (SF1R) was highly expressed in rheumatoid arthritis tissues and cells, and CSF1R over-expression could promote inflammatory responses. Moreover, CSF1R could promote RA-FLS proliferation, inhibit apoptosis and accelerate the cell cycle. The targeting relationship between imatinib and CSF1R was also validated in this study. Imatinib attenuated RA-FLS inflammation in a concentration-dependent manner. Meanwhile, imatinib could inhibit RA-FLS proliferation and promote apoptosis, ultimately reducing the damage of RA-FLS. Over-expression of CSF1R accelerated the cell cycle and proliferation of RA-FLS, while inhibiting cell apoptosis. Conversely, imatinib could significantly restrain the cell cycle and viability of RA-FLS and accelerated apoptosis via suppression of CSF1R expression. Further, histological and serological assay investigated and proved the proinflammatory effects of CSF1R in RA rabbits.
© 2018 British Society for Immunology.

Entities:  

Keywords:  CSF1R; RA-FLS; WGCNA; imatinib; rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 30281780      PMCID: PMC6330650          DOI: 10.1111/cei.13220

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Increased expression of macrophage colony-stimulating factor in ankylosing spondylitis and rheumatoid arthritis.

Authors:  P-T Yang; H Kasai; W-G Xiao; L-J Zhao; L-M He; A Yamashita; X-W Deng; M Ito
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

Review 2.  Targeting monocytes/macrophages in the treatment of rheumatoid arthritis.

Authors:  Jean-Luc Davignon; Myriam Hayder; Michel Baron; Jean-Frédéric Boyer; Arnaud Constantin; Florence Apparailly; Rémy Poupot; Alain Cantagrel
Journal:  Rheumatology (Oxford)       Date:  2012-11-30       Impact factor: 7.580

3.  Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

Authors:  Andrea L Dewar; Antony C Cambareri; Andrew C W Zannettino; Bernadette L Miller; Kathleen V Doherty; Timothy P Hughes; A Bruce Lyons
Journal:  Blood       Date:  2005-01-06       Impact factor: 22.113

4.  c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.

Authors:  Ricardo T Paniagua; Anna Chang; Melissa M Mariano; Emily A Stein; Qian Wang; Tamsin M Lindstrom; Orr Sharpe; Claire Roscow; Peggy P Ho; David M Lee; William H Robinson
Journal:  Arthritis Res Ther       Date:  2010-02-24       Impact factor: 5.156

5.  Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia.

Authors:  K Miyachi; A Ihara; R W Hankins; R Murai; S Maehiro; H Miyashita
Journal:  Clin Rheumatol       Date:  2003-10       Impact factor: 2.980

6.  Is my network module preserved and reproducible?

Authors:  Peter Langfelder; Rui Luo; Michael C Oldham; Steve Horvath
Journal:  PLoS Comput Biol       Date:  2011-01-20       Impact factor: 4.475

7.  The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.

Authors:  Andrea Morandi; Valentina Barbetti; Maria Riverso; Persio Dello Sbarba; Elisabetta Rovida
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

8.  Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis.

Authors:  Takehiro Ota; Hiroshi Urakawa; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Satoshi Tsukushi; Yoshie Shimoyama; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Tumour Biol       Date:  2015-02-18

9.  CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.

Authors:  Ana M Martín-Moreno; Giovanna Roncador; Lorena Maestre; Elena Mata; Scherezade Jiménez; Jorge L Martínez-Torrecuadrada; Ana I Reyes-García; Carmen Rubio; José F Tomás; Mónica Estévez; Karen Pulford; Miguel A Piris; Juan F García
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

10.  Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.

Authors:  M Cioce; C Canino; C Goparaju; H Yang; M Carbone; H I Pass
Journal:  Cell Death Dis       Date:  2014-04-10       Impact factor: 8.469

View more
  3 in total

1.  Coupling of Co-expression Network Analysis and Machine Learning Validation Unearthed Potential Key Genes Involved in Rheumatoid Arthritis.

Authors:  Jianwei Xiao; Rongsheng Wang; Xu Cai; Zhizhong Ye
Journal:  Front Genet       Date:  2021-02-11       Impact factor: 4.599

Review 2.  Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage.

Authors:  Julien Blaess; Julia Walther; Arthur Petitdemange; Jacques-Eric Gottenberg; Jean Sibilia; Laurent Arnaud; Renaud Felten
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-16       Impact factor: 5.346

Review 3.  The M-CSF receptor in osteoclasts and beyond.

Authors:  Se Hwan Mun; Peter Sang Uk Park; Kyung-Hyun Park-Min
Journal:  Exp Mol Med       Date:  2020-08-17       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.